Riddhi Ruparelia
11 posts
With the cost of decoding genes going down, a variety of applications leveraging such information have grown in last few decades.
Our focus in first quarter has been to concentrate only on the best companies going forward and avoid chasing marginal opportunities.
As first quarter earnings came out, most of our companies continued to show tremendous success in their businesses.
We moved money out of Apple (AAPL) and Intuitive Surgical (ISRG) to buy more of holdings in our favorite companies like SodaStream (SODA) and QlikTech (QLIK).
Almost all of our holdings announced Q3 results in October and November and most of them beat Q3 guidance and raised forecasts for Q4.
Skepticism regarding accounting practices has brought down these strong names along with the weaker.
Upside stock price potential now looks not as strong in the large-caps as some of the smaller companies that can grow at a high rate for as long as a decade from now.